Drugs / 6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine
6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02371031 | Mar 2015 → Jul 2016 | malignant glioma | Washington University School of Medicine | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02371031 ↗ |
| Modality | Diagnostic / imaging agent | “FDOPA-PET/MRI” NCT02371031 ↗ |